← Leaderboards
Sheila A Weinmann
Kaiser Foundation Research Institute
$3,662,976
Attributed
$4,858,623
Total exposure
5
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $760K · FY2005–16$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
Funding mix
By agency
NIH$4,858,623 · 5
By mechanism
R01$4,371,573 · 2
R03$487,050 · 3
Top collaborators
- Carolyn Sue Richards4 shared
Most similar at Kaiser Foundation Research Institute
Same institution · by research overlap
- Bette J Caan$23,657,335
- Cheryl K Ritenbaugh$8,224,948
- Candyce H Kroenke$6,952,108
- Ann M. Geiger$1,414,495
- Susanna Decker Mitro$178,068
Others in their field
Top investigators on “Cancer Recurrence”
- Philip J Disaia · University Of California Irvine$95,781,777
- David Heimbrook · Leidos Biomedical Research, Inc.$87,033,539
- John Anthony Baron · Dartmouth College$39,134,760
- Lawrence H Kushi · Kaiser Foundation Research Institute$34,799,252
- Electra D. Paskett · Ohio State University$31,176,895
- Mary M Horowitz · Medical College Of Wisconsin$30,942,523
Research focus
Cancer RecurrenceCessation Of LifeCancer TherapyPharmaceutical PreparationsDiagnosisPathologicRecurrenceAdjuvantReportingNeoplasm /Cancer GeneticsCyp2d6 GeneData AnalysesNeoplasm /Cancer EpidemiologyEffectivenessLeadHormone ReceptorMalignant Breast NeoplasmCase-Control StudiesGenetic VariantHealth PlanningClinical TrialsComputerized Medical RecordBreast Cancer TreatmentAdjuvant Therapy
Grant awards (14)
Statin use in relation to breast cancer recurrence$79,000
R03 · FY2016 · CA · contact PI
Statin use in relation to breast cancer recurrence$79,000
R03 · FY2015 · CA · contact PI
CYP2D6 gene variants and effectiveness of adjuvant tamoxifen in breast cancer$575,924
R01 · FY2014 · CA · contact PI
CYP2D6 gene variants and effectiveness of adjuvant tamoxifen in breast cancer$534,276
R01 · FY2013 · CA · contact PI
CYP2D6 gene variants and effectiveness of adjuvant tamoxifen in breast cancer$613,849
R01 · FY2012 · CA · contact PI
Statins and prostate cancer recurrence$78,299
R03 · FY2012 · CA · contact PI
CYP2D6 gene variants and effectiveness of adjuvant tamoxifen in breast cancer$667,245
R01 · FY2011 · CA · contact PI
Statins and prostate cancer recurrence$92,751
R03 · FY2011 · CA · contact PI
Molecular Epidemiology of Fatal Prostate Cancer$476,732
R01 · FY2006 · CA · contact PI
Molecular Epidemiology of Fatal Prostate Cancer$491,009
R01 · FY2005 · CA
Molecular Epidemiology of Fatal Prostate Cancer$501,022
R01 · FY2004 · CA
Molecular Epidemiology of Fatal Prostate Cancer$511,516
R01 · FY2003 · CA
MOLECULAR EPIDEMIOLOGY OF RENAL CELL CANCER$79,000
R03 · FY2001 · CA
MOLECULAR EPIDEMIOLOGY OF RENAL CELL CANCER$79,000
R03 · FY2000 · CA